Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model

Molecular Pharmaceutics

Volumn 11, Issue 10, 2014, Pages 3515-3527

  Nascimento, Ana Vanessa ^a,b   Singh, Amit ^c   Bousbaa, Hassan ^a,b   Ferreira, Domingos ^b   Sarmento, Bruno ^a,d   Amiji, Mansoor M ^c  

^a INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c NORTHEASTERN UNIVERSITY   (United States)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

chitosan nanoparticles; epidermal growth factor receptor; Mad2 gene; non small cell lung cancer; RNA interference; tumor targeting

Indexed keywords

CHITOSAN; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOPARTICLE; PROTEIN MAD2; SMALL INTERFERING RNA; MAD2L1 PROTEIN, HUMAN;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; MORPHOLOGY; NANOENCAPSULATION; NANOFABRICATION; NON SMALL CELL LUNG CANCER; PARTICLE SIZE; RNA INTERFERENCE; CELL SURVIVAL; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; FLOW CYTOMETRY; GENE SILENCING; HUMANS; MAD2 PROTEINS; NANOPARTICLES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84908009342     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5002894     Document Type: Article

References (59)

1. Zhao, Y.; Lu, H.; Yan, A.; Yang, Y.; Meng, Q.; Sun, L.; Pang, H.; Li, C.; Dong, X.; Cai, L. ABCC3 as a marker for multidrug resistance in non-small cell lung cancer Sci. Rep. 2013, 3, 3120
2. Nascimento, A. V.; Bousbaa, H.; Ferreira, D.; Sarmento, B. Non-small cell lung carcinoma: an overview on targeted therapy. Curr. Drug Targets 2014, PMID 24875380.
3. Saad, M.; Garbuzenko, O. B.; Minko, T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine 2008, 3, 761-776
4. Ashihara, E.; Kawata, E.; Maekawa, T. Future prospect of RNA interference for cancer therapies Curr. Drug Targets 2010, 11, 345-360
5. Bora, R. S.; Gupta, D.; Mukkur, T. K.; Saini, K. S. RNA interference therapeutics for cancer: challenges and opportunities (review) Mol. Med. Rep. 2012, 6, 9-15
6. Kim, D. H.; Rossi, J. J. Strategies for silencing human disease using RNA interference Nat. Rev. Genet. 2007, 8, 173-184
7. Barbosa, J.; Nascimento, A. V.; Faria, J.; Silva, P.; Bousbaa, H. The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy Front. Biol. 2011, 6, 147-155
8. Silva, P.; Barbosa, J.; Nascimento, A. V.; Faria, J.; Reis, R.; Bousbaa, H. Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint Cell Proliferation 2011, 44, 391-400
9. Sotillo, R.; Hernando, E.; Diaz-Rodriguez, E.; Teruya-Feldstein, J.; Cordon-Cardo, C.; Lowe, S. W.; Benezra, R. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice Cancer Cell 2007, 11, 9-23
10. Choi, J. W.; Kim, Y.; Lee, J. H.; Kim, Y. S. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer Virchows Arch. 2013, 463, 681-687
11. Kato, T.; Daigo, Y.; Aragaki, M.; Ishikawa, K.; Sato, M.; Kondo, S.; Kaji, M. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients Lung Cancer 2011, 74, 124-131
12. Yu, L.; Liu, S.; Guo, W.; Zhang, B.; Liang, Y.; Feng, Q. Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression Oncol. Rep. 2012, 28, 2170-2176
13. Furlong, F.; Fitzpatrick, P.; OToole, S.; Phelan, S.; McGrogan, B.; Maguire, A.; OGrady, A.; Gallagher, M.; Prencipe, M.; McGoldrick, A.; McGettigan, P.; Brennan, D.; Sheils, O.; Martin, C.; Eu, W. K.; OLeary, J.; McCann, A. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer J. Pathol. 2012, 226, 746-755
14. Wang, L.; Yin, F.; Du, Y.; Chen, B.; Liang, S.; Zhang, Y.; Du, W.; Wu, K.; Ding, J.; Fan, D. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin Tumour Biol. 2010, 31, 225-232
15. Fung, M. K.; Cheung, H. W.; Wong, H. L.; Yuen, H. F.; Ling, M. T.; Chan, K. W.; Wong, Y. C.; Cheung, A. L.; Wang, X. MAD2 expression and its significance in mitotic checkpoint control in testicular germ cell tumour Biochim. Biophys. Acta 2007, 1773, 821-832
16. Cheung, H. W.; Jin, D. Y.; Ling, M. T.; Wong, Y. C.; Wang, Q.; Tsao, S. W.; Wang, X. Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells Cancer Res. 2005, 65, 1450-1458
17. Michel, L. S.; Liberal, V.; Chatterjee, A.; Kirchwegger, R.; Pasche, B.; Gerald, W.; Dobles, M.; Sorger, P. K.; Murty, V. V.; Benezra, R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells Nature 2001, 409, 355-359
18. Michel, L.; Diaz-Rodriguez, E.; Narayan, G.; Hernando, E.; Murty, V. V.; Benezra, R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4459-4464
19. Manchado, E.; Guillamot, M.; Malumbres, M. Killing cells by targeting mitosis Cell Death Differ. 2012, 19, 369-377
20. Burnett, J. C.; Rossi, J. J. RNA-based therapeutics: current progress and future prospects Chem. Biol. 2012, 19, 60-71
21. Aigner, A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo Appl. Microbiol. Biotechnol. 2007, 76, 9-21
22. Ganesh, S.; Iyer, A. K.; Morrissey, D. V.; Amiji, M. M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors Biomaterials 2013, 34, 3489-3502
23. Ganesh, S.; Iyer, A. K.; Gattacceca, F.; Morrissey, D. V.; Amiji, M. M. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles J. Controlled Release 2013, 172, 699-706
24. Ganesh, S.; Iyer, A. K.; Weiler, J.; Morrissey, D. V.; Amiji, M. M. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer Mol. Ther. 2013, 2, e110
25. Jean, M.; Alameh, M.; De Jesus, D.; Thibault, M.; Lavertu, M.; Darras, V.; Nelea, M.; Buschmann, M. D.; Merzouki, A. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes Eur. J. Pharm. Sci. 2012, 45, 138-149
26. Lai, W. F.; Lin, M. C. Nucleic acid delivery with chitosan and its derivatives J. Controlled Release 2009, 134, 158-168
27. Jean, M.; Smaoui, F.; Lavertu, M.; Methot, S.; Bouhdoud, L.; Buschmann, M. D.; Merzouki, A. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies Gene Ther. 2009, 16, 1097-1110
28. Ragelle, H.; Vandermeulen, G.; Preat, V. Chitosan-based siRNA delivery systems J. Controlled Release 2013, 172, 207-218
29. Koppolu, B. P.; Smith, S. G.; Ravindranathan, S.; Jayanthi, S.; Suresh Kumar, T. K.; Zaharoff, D. A. Controlling chitosan-based encapsulation for protein and vaccine delivery Biomaterials 2014, 35, 4382-4389
30. Scherliess, R.; Buske, S.; Young, K.; Weber, B.; Rades, T.; Hook, S. In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations Vaccine 2013, 31, 4812-4819
31. Andrade, F.; Antunes, F.; Nascimento, A. V.; da Silva, S. B.; das Neves, J.; Ferreira, D.; Sarmento, B. Chitosan formulations as carriers for therapeutic proteins Curr. Drug Discovery Technol. 2011, 8, 157-172
32. Agnihotri, S. A.; Mallikarjuna, N. N.; Aminabhavi, T. M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery J. Controlled Release 2004, 100, 5-28
33. Park, J. H.; Saravanakumar, G.; Kim, K.; Kwon, I. C. Targeted delivery of low molecular drugs using chitosan and its derivatives Adv. Drug Delivery Rev. 2010, 62, 28-41
34. Schafer, A.; Pahnke, A.; Schaffert, D.; van Weerden, W. M.; de Ridder, C. M.; Rodl, W.; Vetter, A.; Spitzweg, C.; Kraaij, R.; Wagner, E.; Ogris, M. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation Human Gene Ther. 2011, 22, 1463-1473
35. Milane, L.; Duan, Z. F.; Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer Nanomedicine 2011, 7, 435-444
36. Milane, L.; Duan, Z.; Amiji, M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells Mol. Pharmaceutics 2011, 8, 185-203
37. Xu, J.; Singh, A.; Amiji, M. M. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer BMC Cancer 2014, 14, 75
38. Ganta, S.; Singh, A.; Patel, N. R.; Cacaccio, J.; Rawal, Y. H.; Davis, B. J.; Amiji, M. M.; Coleman, T. P. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm. Res. 2014, PMID: 24643932.
39. Milane, L.; Duan, Z.; Amiji, M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer PLoS One 2011, 6, e24075
40. Xu, J.; Gattacceca, F.; Amiji, M. Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice Mol. Pharmaceutics 2013, 10, 2031-2044
41. Li, Z.; Zhao, R.; Wu, X.; Sun, Y.; Yao, M.; Li, J.; Xu, Y.; Gu, J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics FASEB J. 2005, 19, 1978-1985
42. Malmo, J.; Sandvig, A.; Varum, K. M.; Strand, S. P. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach PLoS One 2013, 8, e54182
43. Fan, Z.; Lu, Y.; Wu, X.; Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells J. Biol. Chem. 1994, 269, 27595-27602
44. Maya, S.; Sarmento, B.; Lakshmanan, V. K.; Menon, D.; Seabra, V.; Jayakumar, R. Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells Int. J. Biol. Macromol. 2014, 69, 532-541
45. Howard, K. A.; Rahbek, U. L.; Liu, X.; Damgaard, C. K.; Glud, S. Z.; Andersen, M. O.; Hovgaard, M. B.; Schmitz, A.; Nyengaard, J. R.; Besenbacher, F.; Kjems, J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system Mol. Ther. 2006, 14, 476-484
46. Huang, M.; Khor, E.; Lim, L. Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation Pharm. Res. 2004, 21, 344-353
47. Hirsch, F. R.; Scagliotti, G. V.; Langer, C. J.; Varella-Garcia, M.; Franklin, W. A. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies Lung Cancer 2003, 41, S29-S42
48. Scagliotti, G. V.; Selvaggi, G.; Novello, S.; Hirsch, F. R. The biology of epidermal growth factor receptor in lung cancer Clin. Cancer Res. 2004, 10, 4227s-4232s
49. Kurai, J.; Chikumi, H.; Hashimoto, K.; Yamaguchi, K.; Yamasaki, A.; Sako, T.; Touge, H.; Makino, H.; Takata, M.; Miyata, M.; Nakamoto, M.; Burioka, N.; Shimizu, E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clin. Cancer Res. 2007, 13, 1552-1561
50. Proske, D.; Blank, M.; Buhmann, R.; Resch, A. Aptamers-basic research, drug development, and clinical applications Appl. Microbiol. Biotechnol. 2005, 69, 367-374
51. Prabha, S.; Zhou, W. Z.; Panyam, J.; Labhasetwar, V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles Int. J. Pharm. 2002, 244, 105-115
52. Langlois, M. A.; Boniface, C.; Wang, G.; Alluin, J.; Salvaterra, P. M.; Puymirat, J.; Rossi, J. J.; Lee, N. S. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells J. Biol. Chem. 2005, 280, 16949-16954
53. Robb, G. B.; Brown, K. M.; Khurana, J.; Rana, T. M. Specific and potent RNAi in the nucleus of human cells Nat. Struct. Mol. Biol. 2005, 12, 133-137
54. Berezhna, S. Y.; Supekova, L.; Supek, F.; Schultz, P. G.; Deniz, A. A. siRNA in human cells selectively localizes to target RNA sites Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7682-7687
55. Guang, S.; Bochner, A. F.; Pavelec, D. M.; Burkhart, K. B.; Harding, S.; Lachowiec, J.; Kennedy, S. An Argonaute transports siRNAs from the cytoplasm to the nucleus Science 2008, 321, 537-541
56. Liu, X.; Howard, K. A.; Dong, M.; Andersen, M. O.; Rahbek, U. L.; Johnsen, M. G.; Hansen, O. C.; Besenbacher, F.; Kjems, J. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing Biomaterials 2007, 28, 1280-1288
57. Fernandes, J. C.; Qiu, X.; Winnik, F. M.; Benderdour, M.; Zhang, X.; Dai, K.; Shi, Q. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies Int. J. Nanomed. 2012, 7, 5833-5845
58. Xu, D.; McCarty, D.; Fernandes, A.; Fisher, M.; Samulski, R. J.; Juliano, R. L. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector Mol. Ther. 2005, 11, 523-530
59. Lee, S. M. Is EGFR expression important in non-small cell lung cancer? Thorax 2006, 61, 98-99